Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyslipidemia and Anti-VEGF Response in DME
NCT06205979Phase 1Recruiting
- Sponsor
- Sohag University
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ranibizumab and aflibercept in diabetic macular edema (DME), sponsored by Sohag University. Primary endpoint: Best Corrected Visual Acuity at 2 months. Started Dec 2023; status: recruiting.
02
Drugs
ranibizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06205979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205979.